Heparin toxicity in cell culture: A critical link in translation of basic science to clinical practice

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 7, 2013, Pages 742-745

  Gurbuz, H Alper ^a,b   Durukan, A Baris ^a,b   Sevim, Handan ^b   Ergin, Ekin ^a   Gurpinar, Aylin ^b   Yorgancioglu, Cem ^a  

^a ANKARA NUMUNE HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

cell culture techniques; heparin; toxicity

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; HEPARIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DENSITY; CELL VIABILITY; CLINICAL PRACTICE; CONTROLLED STUDY; CYTOTOXICITY; FIBROBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICOAGULANTS; CELL CULTURE TECHNIQUES; FIBROBLASTS; HEPARIN; MICE;

EID: 84885128993     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283629bbc     Document Type: Article

References (22)

1. Mandal AK, Lyden TW, Saklayen MG. Heparin lowers blood pressure: biological and clinical perspectives. Kidney Int 1995; 47:1017-1022.
2. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L-and P-selectin and inhibit acute inflammation. Blood 1993; 82:3253-3258. (Pubitemid 23356692)
3. Reilly CF, Fritze LM, Rosenberg RD. Heparin inhibition of smooth muscle cell proliferation: a cellular site of action. J Cell Physiol 1986; 129:11-19. (Pubitemid 17178520)
4. Cosmi B, Palareti G. Old and new heparins. Thromb Res 2012; 129:388-391.
5. Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Lau A, et al. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 2007; 92:554-557. (Pubitemid 350144302)
6. Hiebert LM, Wice SM, McDuffie NM, Jaques LB. The heparin target organthe endothelium. Studies in rat model. Q J Med 1993; 86:341-348. (Pubitemid 23160835)
7. Durukan AB, Erdem B, Durukan E, Sevim H, Karaduman T, Gurbuz HA, et al. May toxicity of amiodorone be prevented by antioxidants? A cell-culture study. J Cardiothorac Surg 2012; 7:61.
8. Carmichael J, DeGraff WG,Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47:943-946. (Pubitemid 17027906)
9. Mrabat H, Garg HG, Hales CA. Growth inhibition of bovine pulmonary artery smooth muscle cells following long term heparin treatment. J Cell Physiol 2009; 221:603-608.
10. Lovich MA, Edelman ER. Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo. Proc Natl Acad Sci USA 1999; 96:11111-11116. (Pubitemid 29487342)
11. Katzung BG. Drugs used in disorders of coagulation. In: Katzung BG, editor. Basic and clinical pharmacology, 12th ed. Lange; 2012. pp. 759-778.
12. Erduran E, Tekelioglu Y, Gedik Y, Yildiran A. Apoptotic effects of heparin on lymphoblasts, neutrophils, and mononuclear cells: results of a preliminary in vitro study. Am J Hematol 1999; 61:90-93. (Pubitemid 29252383)
13. O'donnell J. Anticoagulants: therapeutics, risks and toxicity: special emphasis on heparin-induced thrombocytopenia. J Pharm Pract 2012; 25:22-29.
14. Krishnaswamy A, Lincoff AM, Cannon CP. Bleeding complications of unfractionated heparin. Expert Opin Drug Saf 2011; 10:77-84.
15. Rajgopal R, Bear M, Butcher MK, Shaughnessy SG. Effects of heparin and low molecular weight heparins on bone. Thromb Res 2008; 122:293-298. (Pubitemid 351888881)
16. Monagle P, Studdert DM, Nevall F. Infant deaths due to heparin overdose: time for a concerted action on prevention. J Paediatr Child Health 2012; 48:380-381.
17. Valenstein PN, Walsh MK, Meier F. College of American Pathologists. Heparin monitoring and patient safety: a Collage of American Pathologists Q-Probes study of 3431 patients at 140 institutions. Arch Pathol Lad Med 2004; 128:397-402. (Pubitemid 38451125)
18. Newall F, Johnston L, Ignjatovic V, Monagle P. Unfractionated heparin theraphy in infants and children. Pediatrics 2009; 123:510-518.
19. Bharadwaj J, Jayaraman C, Shrivastava R. Heparin resistance. Lab Heametol 2003; 9:125-131. (Pubitemid 37220791)
20. Paparella D, Al Radi OO, Meng QH, Venner T, Teoh K, Young E. The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass. Blood Coagul Fibrinolysis 2005; 16:323-328. (Pubitemid 41008738)
21. Yamashita Y, Nakagomi K, Takeda D, Hasegawa S, Mitsui Y. Effect of heparin on pulmonary fibroblasts and vascular cells. Thorax 1992; 47:634-639.
22. Denk PO, Knorr M. Effect of heparin on human corneal fibroblast proliferation in vitro with and without growth factor stimulation. Graefes Arch Clin Exp Ophthalmol 1999; 237:342-347. (Pubitemid 29145813)